Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update
- 8 May 2012
- journal article
- Published by Wiley in Hepatology Research
- Vol. 42 (6), 523-542
- https://doi.org/10.1111/j.1872-034x.2012.00981.x
Abstract
The “Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular Carcinoma” was prepared by the Study Group on New Liver Cancer Therapies established by the “Research Project on Emergency Measures to Overcome Hepatitis” under the auspices of the Health and Labour Sciences Research Grant. The Guideline brings together data collected by the Study Group on the use and incidence of adverse events in 264 patients with advanced hepatocellular carcinoma (HCC) treated using sorafenib and in 535 patients with advanced HCC treated using miriplatin at 16 participating institutions up until 22 December 2010, as well as referring to the published studies, academic presentations, and reports from the private sector. The aim of this Guideline is to facilitate understanding and current thinking regarding the proper usage of new anticancer drugs towards actual use in therapy. In terms of the format, the Guideline presents “clinical questions” on issues pertaining to medical care, makes “recommendations” on diagnosis and treatment in response to each of these clinical questions, and provides a rationale for these recommendations in the form of “scientific statements”.Keywords
This publication has 24 references indexed in Scilit:
- Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosisOncology Reports, 2010
- Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinomaCancer, 2010
- Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) studyInternational Journal of Clinical Practice, 2010
- Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II studyRadiation Oncology, 2010
- Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and Child-Pugh B liver cirrhosisKanzo, 2010
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudyBMC Medicine, 2009
- Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenibBMC Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Phase I study of sorafenib in Japanese patients with hepatocellular carcinomaCancer Science, 2007
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006